Abstract:Objective: To investigate the value of XRCC1 gene DNA methylation in predicting the efficacy of oxaliplatin-based adjuvant chemotherapy in patients with gastric cancer. Methods: A total of 116 patients with gastric cancer received at least 6 cycles of combination chemotherapy of oxaliplatin and fluorouracil. Bisulfite sequencing was used to analyze the methylation of XRCC1 gene in gastric cancer surgical specimens, and the correlation with the efficacy of chemotherapy in patients with gastric cancer were also analyzed. Results: There was no statistically significant difference in the average methylation rates of XRCC1 gene among gastric cancer patients with different gender, age, lymph node metastasis, tumor diameters, differentiation, and whether they received adjuvant chemotherapy (P>0.05) . The average survival time of gastric cancer patients receiving chemotherapy and not receiving chemotherapy were (42.82±3.57) months and (25.68±4.90) months, respectively. The survival time of gastric cancer patients receiving chemotherapy was longer (χ2=7.208, P=0.007) . The average methylation rate of chemotherapy effective group was 51.60%, and that of chemotherapy ineffective group was 38.31%, with significant differences between the two groups (P<0.05) . Conclusion: The DNA methylation rate of XRCC1 gene is positively correlated with the sensitivity of oxaliplatin, which is a potential molecular marker to predict the efficacy and prognosis of chemotherapy in patients with gastric cancer.
